Trial Profile
A Randomized, Open-label, Parallel Controlled, Multi-center Phase III Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Chemotherapy as Second-line Treatment in Subjects With Advanced Biliary Cancer
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Mar 2023
Price :
$35
*
At a glance
- Drugs Benmelstobart (Primary) ; Catequentinib (Primary) ; Capecitabine; Gemcitabine; Oxaliplatin
- Indications Adenocarcinoma; Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
- Focus Registrational; Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 24 Mar 2021 New trial record